Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia
NCT00036257
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG:
CP-461
Sponsor
Astellas Pharma Inc
Collaborators
[object Object]
[object Object]